Competitor Analysis: Immunocytokines

Cytokine-engineering as a measure to reduce dose-limiting toxicities of immunocytokines

The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins,  has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety.

The present Competitive Intelligence report about Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.